Gilead Sciences
Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.
BioNTech to Acquire Gilead/Kite's TCR Therapy Program, Manufacturing Facility
The deal will give BioNTech a North American footprint while allowing Gilead subsidiary Kite to focus exclusively on commercializing its CAR T-cell therapies.Â
Gilead's Yescarta Improves Large B-Cell Lymphoma Patients' Outcomes Over Standard Care in Zuma-7
Gilead company Kite is initiating talks with regulators and is planning to seek marketing approval for the CAR T-cell therapy for second-line LBCL.
EHA Virtual Congress 2021 Roundup: Roche, Mustang Bio, Gilead, Innovent, Autolus, Curis
Companies presented the latest data on precision oncology therapeutics for blood cancers at the meeting held from June 9-17.
Humanigen's Lenzilumab With CAR T-Cell Therapy Improves Response in Lymphoma
The firm will initiate a Phase II registrational study of lenzilumab with all commercially available CD19 CAR T-cell therapies in diffuse large B-cell lymphoma.